Navigation Links
Weeding out marijuana: Researchers close in on engineering recognizable, drug-free Cannabis plant
Date:9/15/2009

United States until legislation outlawed all Cannabis plants because they contain THC. Today, marijuana contains as much as 25 percent THC, whereas hemp plants contain less than 0.3 percent.

Hemp was once a popular crop in the upper Midwest because it tolerates a cool climate and marginal soils that won't support other crops but, after drug legislation, hemp fiber was replaced by plastic and other alternatives. Recent popular demand for hemp products has led some states to consider the economic and environmental benefits of hemp. North Dakota legislation aims to reintroduce it as a crop, and Minnesota is considering similar legislation. At the same time, California and other states permit the medicinal use of marijuana.

"I can't think of a plant so regarded as a menace by some and a miracle by others," says Weiblen, who is one of the few researchers in the United States permitted to study Cannabis genetics. In 2006, Weiblen and colleagues developed a DNA "fingerprinting" technique capable of distinguishing among Cannabis plants in criminal investigations.


'/>"/>

Contact: Patty Mattern
mattern@umn.edu
612-624-2801
University of Minnesota
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Our brains make their own marijuana: Were all pot heads deep inside
2. Dartmouth researchers get personal with genetics
3. Ecosystem researchers to hold science briefing for policymakers
4. UAB researchers looking for genetic predictors for suicide
5. Rice researchers seek better vaccine procedure
6. Researchers find first evidence of virus in malignant prostate cells
7. Diabetes advance: Researchers find gene that causes resistance to insulin
8. Researchers find 2 more genetic risk factors for Alzheimers disease
9. Researchers restore missing protein in rare genetic brain disorder
10. Mayo Clinic researchers find that protein believed to protect against cancer has a Mr. Hyde side
11. Species diversity helps ASU researchers refine analyses of human gene mutations

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...s opening new doors to understanding how sounds as...of a marine mammal or if they hear it at all. , ...nners that NASA uses to detect flaws in the space ...ing scientists to peek inside the giant head of a ...nsional replicas of a whale,s hearing anatomy usin...
(Date:11/24/2009)... weakened and flabby arteries from collapsing have...e stents are no longer needed -- once the arteries...usly, doctors had no choice but to leave them in p...rsity,s Department of Biomedical Engineering has d...carries drugs where they,re needed, then dissolves...
(Date:11/24/2009)... American College of Medical Toxicology (ACMT) hav...ation of the Journal of Medical Toxicology (JMT)...arch 2010. It was previously published by the Uni...f Medical Toxicology , an international, peer-revi...e and practice of medical toxicology. The quarter...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2A coating for life 2Springer and the American College of Medical Toxicology to work together 2Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 1Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 2Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 3Brookhaven Lab and Hybridyne Imaging Technologies Inc win R 26amp 3BD 100 award 52619 1Brookhaven Lab and Hybridyne Imaging Technologies Inc win R 26amp 3BD 100 award 52619 2Brookhaven Lab and Hybridyne Imaging Technologies Inc win R 26amp 3BD 100 award 52619 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 1R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 4R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 5R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 6R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 7R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 8
...dy of 20,000 people found seven new genes that inf... heart disease, and confirmed 11 other genes prev...nternational study led by researchers from the Uni...t to identify or confirm genetic variants that inf... variants were linked to the decreased or increase...
...he human genome, researchers have associated level...e blood, to 18 genetic variants, six of which repr... the traits. The findings, appearing in the Januar... explain some of the variability in cholesterol an... the potential to help predict a patients genetic ...
...) brings experts to New York City from around the ...ce on Cell Therapy for Cardiovascular Diseases. De...e three-day session will feature an in-depth revie...d regeneration, angiogenesis and cutting-edge rese...al Focus: Full-day programs for the discussion of...
Other Biology News:Study locates cholesterol genes; finds surprises about good, bad cholesterol 2Scientists associate 6 new genetic variants with heart disease risk factor 2Scientists associate 6 new genetic variants with heart disease risk factor 3Scientists associate 6 new genetic variants with heart disease risk factor 4Cell Therapy for Cardiovascular Diseases 2Cell Therapy for Cardiovascular Diseases 3
(Date:11/24/2009)...e-FirstCall/--IES(Nasdaq: IESC ),aleadingnationalp...icesforthecommercial,industrialandresidentialmarke...beenawardedacontractfromManhattanTorconJVtoinstall...4)replacementfacilityattheU.S.ArmyMedicalResearchI...kinFrederick,Md. ,, ThenewUSAMRIIDreplacementfa...
(Date:11/24/2009)...w York investment bank KTA Capital,s client Neuren...7 mil convertible note private placement with a U....as arranged by KTA Capital as Neuren,s exclusive p... New York (PRWEB) November 23, 2009 -- The ind... ("KTA Capital") has announced that its ...
(Date:11/24/2009)...io,Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCa...eds,adivisionofThompsonsLimitedofBlenheim,Ontario....iences,currentseedsbusinessasthecompanyanticipates...roSciencesHerbicideTolerantTraitTechnologyincornin...e. ,, "Thisacquisitionbringstogethertwostrongpr...
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
Breaking Biology Technology:Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3
...rovide sustained tumor exposure to platinum and pr...icity observed in the clinic - , , DALLAS, April ...oard: ACCP) announced today that its collaborato... preclinical data on its lead anticancer compound,...ncer Research (AACR) Annual Meeting taking place A...
...April 21 /PRNewswire-Asia/ --,QIAGEN and the Chitt...ounced a,collaboration to establish the first larg...n in Kolkata, India. QIAGEN (Nasdaq: QGEN ; Fra...ostic tests for the human papillomavirus,(HPV) -- ...nduct the screening,and provide appropriate treatm...
...L ), a leading, global full-service clinical resea... meet analyst expectations for the first quarter o...ecedented biopharmaceutical industry conditions, w... of contracts on existing awards, fewer new reques...llations and delays. The Company now expects net s...
Other Biology Technology:Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting 2Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting 3Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting 4QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 2QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 3QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 4QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 5Kendle to Host Conference Call to Discuss Revised 2009 Outlook 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 3
Stainless Steel Glove Boxes from Terra Universal, Inc.
...n filter/fan unit provides continuous vertical flo...SO 5) cleanliness standards , Stainless steel en...ergonomically sloped polycarbonate viewing window ...or other large process equipment , Isolated ante...
Heated Processing Chamber from Terra Universal, Inc.
Down Draft Work Station from Terra Universal, Inc.
Biology Products: